ArticleThe Journal of clinical investigation2018
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
Article in The Journal of clinical investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06056791 (An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy), which is not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Pooled it
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Deciphering molecular pathways in urological cancers: A gateway to precision therapeutics.Journal of advanced research · 2026Review
- Pentagalloyl Glucose (PGG) Exhibits Anti-Cancer Activity against Aggressive Prostate Cancer by Modulating the ROR1 Mediated AKT-GSK3β Pathway.International journal of molecular sciences · 2024Article
- B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.European urology · 2023Article
- Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting.European urology open science · 2023Article
- Identification of novel molecular subtypes and a signature to predict prognosis and therapeutic response based on cuproptosis-related genes in prostate cancer.Frontiers in oncology · 2023Article
- Article
- Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report.Frontiers in oncology · 2022Article
- An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT.International journal of molecular sciences · 2021Review
- Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy.Acta pharmaceutica Sinica. B · 2021Review
- Article
- Rapidly evolving treatment paradigm and considerations for sequencing therapies in metastatic prostate cancer-a narrative review.Translational andrology and urology · 2021Review
- Prostate Cancer Immunotherapy-Finally in From the Cold?Current oncology reports · 2021Review
- CD38 in Advanced Prostate Cancers.European urology · 2021Article
- EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.Nature cancer · 2021Article
- Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling.Nature communications · 2021Article
- Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinoma.Cancer immunology, immunotherapy : CII · 2021Article
Corrections and comments
- Erratum for
Authors and funding
52 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.